(Reuters) - Merck & Co on Monday said it expects next year to seek U.S. approval for its experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary effectiveness goals in a late-stage trial. The drug significantly reduced risk of fractures of the hip and spine, and of non-vertebral fractures, compared with placebo, Merck said in a release. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment